Oculis (NASDAQ:OCS) Shares Down 4.3% – Time to Sell?

Shares of Oculis Holding AG (NASDAQ:OCS) dropped 4.3% during mid-day trading on Monday . The company traded as low as $20.33 and last traded at $20.3460. Approximately 118,649 shares traded hands during mid-day trading, an increase of 105% from the average daily volume of 57,834 shares. The stock had previously closed at $21.25.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on OCS shares. Chardan Capital restated a “buy” rating and issued a $51.00 target price on shares of Oculis in a report on Tuesday, November 11th. JPMorgan Chase & Co. assumed coverage on shares of Oculis in a report on Friday. They issued an “overweight” rating and a $38.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Oculis in a research report on Wednesday, October 8th. Lifesci Capital started coverage on shares of Oculis in a research note on Wednesday, December 3rd. They set an “outperform” rating and a $55.00 target price on the stock. Finally, Bank of America dropped their price target on shares of Oculis from $30.00 to $29.00 and set a “buy” rating for the company in a research note on Thursday, November 13th. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $41.50.

Oculis Trading Down 4.2%

The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.47 and a current ratio of 4.47. The firm has a market capitalization of $1.07 billion, a price-to-earnings ratio of -8.08 and a beta of 0.32. The business has a fifty day moving average price of $20.10 and a 200 day moving average price of $18.86.

Oculis (NASDAQ:OCS) last issued its earnings results on Monday, November 10th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.10. The firm had revenue of $0.31 million for the quarter, compared to analysts’ expectations of $0.23 million. Oculis had a negative return on equity of 80.82% and a negative net margin of 12,915.42%. As a group, equities analysts forecast that Oculis Holding AG will post -2.09 earnings per share for the current year.

Institutional Investors Weigh In On Oculis

Several institutional investors have recently bought and sold shares of OCS. Pivotal bioVenture Partners Investment Advisor LLC raised its stake in shares of Oculis by 32.4% in the 1st quarter. Pivotal bioVenture Partners Investment Advisor LLC now owns 2,300,774 shares of the company’s stock valued at $43,784,000 after acquiring an additional 563,078 shares during the period. Alyeska Investment Group L.P. purchased a new stake in Oculis during the 1st quarter worth $2,499,000. Compagnie Lombard Odier SCmA increased its holdings in Oculis by 11.5% in the 2nd quarter. Compagnie Lombard Odier SCmA now owns 97,000 shares of the company’s stock valued at $1,883,000 after purchasing an additional 10,000 shares in the last quarter. Woodline Partners LP grew its stake in shares of Oculis by 65.8% in the third quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock valued at $1,474,000 after buying an additional 33,265 shares in the last quarter. Finally, Bank of America Corp DE lifted its position in Oculis by 2.2% during the 2nd quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock worth $786,000 after acquiring an additional 878 shares in the last quarter. 22.30% of the stock is currently owned by hedge funds and other institutional investors.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.